Detecting Thrombophilia, Hypofibrinolysis and Reduced Nitric Oxide Production in Osteonecrosis

Seminars in Arthroplasty JSES

Volumn 18, Issue 3, 2007, Pages 184-191

  Glueck, Charles J ^a   Freiberg, Richard A ^b   Wang, Ping ^a  

^a JEWISH HOSPITAL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

hypofibrinolysis; osteonecrosis; reduced nitric oxide production; thrombophilia

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; CARDIOLIPIN ANTIBODY; CYANOCOBALAMIN; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENOXAPARIN; ESTROGEN; FOLIC ACID; HOMOCYSTEINE; LIPOPROTEIN A; NITRIC OXIDE; PLASMINOGEN ACTIVATOR INHIBITOR; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTHROMBIN; PYRIDOXINE; WARFARIN;

AMINO ACID SUBSTITUTION; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD CLOTTING DISORDER; BONE NECROSIS; CLINICAL TRIAL; FEMUR HEAD NECROSIS; FIBRINOLYSIS; GENE MUTATION; HUMAN; HYPERHOMOCYSTEINEMIA; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PERTHES DISEASE; PREGNANCY; RISK FACTOR; THROMBOPHILIA; VEIN OCCLUSION; VEIN THROMBOSIS;

EID: 34548295107     PISSN: 10454527     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.sart.2007.06.005     Document Type: Article

References (96)

1. Bjorkman A., Burtscher I.M., Svensson P.J., et al. Factor V Leiden and the prothrombin 20210A gene mutation and osteonecrosis of the knee. Arch Orthop Trauma Surg 125 (2005) 51-55
2. Jones J.P. Risk factors potentially activating intravascular coagulation and causing nontraumatic osteonecrosis. In: Urbaniak J.R., and Jones Jr. J.P. (Eds). Osteonecrosis: Etiology, Diagnosis, and Treatment (1997), American Academy of Orthopaedic Surgeons, Rosemont, IL 89-97
3. Jones L.C., Mont M.A., Le T.B., et al. Procoagulants and osteonecrosis. J Rheumatol 30 (2003) 783-791
4. Jones L.C., and Hungerford D.S. Osteonecrosis: Etiology, diagnosis, and treatment. Curr Opin Rheumatol 16 (2004) 443-449
5. Glueck C.J., Glueck H.I., Mieczkowski L., et al. Familial high plasminogen activator inhibitor with hypofibrinolysis, a new pathophysiologic cause of osteonecrosis?. Thromb Haemost 69 (1993) 460-465
6. Glueck C.J., Freiberg R., Glueck H.I., et al. Idiopathic osteonecrosis, hypofibrinolysis, high plasminogen activator inhibitor, high lipoprotein(a), and therapy with Stanozolol. Am J Hematol 48 (1995) 213-220
7. Glueck C.J., Freiberg R., Tracy T., et al. Thrombophilia and hypofibrinolysis: Pathophysiologies of osteonecrosis. Clin Orthop (1997) 43-56
8. Glueck C.J., Fontaine R.N., Gruppo R., et al. The plasminogen activator inhibitor-1 gene, hypofibrinolysis, and osteonecrosis. Clin Orthop (1999) 133-146
9. Glueck C.J., Freiberg R.A., Fontaine R.N., et al. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop (2001) 19-33
10. Glueck C.J., Freiberg R.A., Sieve L., et al. Enoxaparin prevents progression of stages I and II osteonecrosis of the hip. Clin Orthop Relat Res (2005) 164-170
11. Glueck C.J.F.R., Oghene J., Fontaine R.N., et al. Association Between the T-786C eNOS polymorphism and idiopathic osteonecrosis of the head of the femur. J Bone Joint Surg Am (2007) (in press)
12. Glueck C.J.F.R., Oghene J., Fontaine R.N., et al. Association between the T-786C eNOS polymorphism and idiopathic osteonecrosis of the hip. J Invest Med Abstr (2007) (in press)
13. Koo K.H., Lee J.S., Lee Y.J., et al. Endothelial nitric oxide synthase gene polymorphisms in patients with nontraumatic femoral head osteonecrosis. J Orthop Res 24 (2006) 1722-1728
14. Arlet J., and Ficat P. Diagnosis of primary femur head osteonecrosis at stage 1 (preradiologic stage). Rev Chir Orthop Reparatrice Appar Motil 54 (1968) 637-648
15. Glueck C.J., Glueck H.I., Tracy T., et al. Inheritance conjointly contributing to fibrinolysis and hyperlipidemia. Metabolism 42 (1993) 1410-1419
16. Wahlander K., Larson G., Lindahl T.L., et al. Factor V Leiden (G1691A) and prothrombin gene G20210A mutations as potential risk factors for venous thromboembolism after total hip or total knee replacement surgery. Thromb Haemost 87 (2002) 580-585
17. Westrich G.H., Weksler B.B., Glueck C.J., et al. Correlation of thrombophilia and hypofibrinolysis with pulmonary embolism following total hip arthroplasty: An analysis of genetic factors. J Bone Joint Surg Am 84A (2002) 2161-2167
18. Salvati E.A., Della Valle A.G., Westrich G.H., et al. The John Charnley Award: Heritable thrombophilia and development of thromboembolic disease after total hip arthroplasty. Clin Orthop Relat Res 441 (2005) 40-55
19. Mont M.A., Jones L.C., Rajadhyaksha A.D., et al. Risk factors for pulmonary emboli after total hip or knee arthroplasty. Clin Orthop Relat Res 422 (2004) 154-163
20. Assouline-Dayan Y., Chang C., Greenspan A., et al. Pathogenesis and natural history of osteonecrosis. Semin Arthritis Rheum 32 (2002) 94-124
21. Ficat P. Cortisone associated necrosis of bone. In: Hungerford D. (Ed). Ischemia and Necrosis of Bone (1980), Williams and Wilkins, Baltimore, MD 171-176
22. McKee M.D., Waddell J.P., Kudo P.A., et al. Osteonecrosis of the femoral head in men following short-course corticosteroid therapy: A report of 15 cases. Can Med Assoc J 164 (2001) 205-206
23. Van Veldhuizen P.J., Neff J., Murphey M.D., et al. Decreased fibrinolytic potential in patients with idiopathic avascular necrosis and transient osteoporosis of the hip. Am J Hematol 44 (1993) 243-248
24. Glueck C.J., Glueck H.I., Greenfield D., et al. Protein C and S deficiency, thrombophilia, and hypofibrinolysis: pathophysiologic causes of Legg-Perthes disease. Pediatr Res 35 (1994) 383-388
25. Glueck C.J., McMahon R.E., Bouquot J., et al. Thrombophilia, hypofibrinolysis, and alveolar osteonecrosis of the jaws. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 81 (1996) 557-566
26. Glueck C.J., Crawford A., Roy D., et al. Association of antithrombotic factor deficiencies and hypofibrinolysis with Legg-Perthes disease. J Bone Joint Surg Am 78 (1996) 3-13
27. Glueck C.J., McMahon R.E., Bouquot J.E., et al. Heterozygosity for the Leiden mutation of the factor V gene, a common pathoetiology for osteonecrosis of the jaw, with thrombophilia augmented by exogenous estrogens. J Lab Clin Med 130 (1997) 540-543
28. Glueck C.J., Brandt G., Gruppo R., et al. Resistance to activated protein C and Legg-Perthes disease. Clin Orthop (1997) 139-152
29. Glueck C.J., Freiberg R.A., Crawford A., et al. Secondhand smoke, hypofibrinolysis, and Legg-Perthes disease. Clin Orthop (1998) 159-167
30. Glueck C.J., McMahon R.E., Bouquot J.E., et al. Exogenous estrogen may exacerbate thrombophilia, impair bone healing and contribute to development of chronic facial pain. Cranio 16 (1998) 143-153
31. Glueck C.J., Phillips H.G., Cameron D., et al. Estrogen replacement in a protein S deficient patient leads to diarrhea, hyperglucagonemia, and osteonecrosis. Journal of the Pancreas 2 (2001) 323-329
32. Glueck C.J., Freiberg R.A., Fontaine R.N., et al. Anticoagulant therapy for osteonecrosis associated with heritable hypofibrinolysis and thrombophilia. Expert Opin Invest Drugs 10 (2001) 1309-1316
33. Glueck C.J., Freiberg R.A., and Wang P. Role of thrombosis in osteonecrosis. Curr Hematol Rep 2 (2003) 417-422
34. Gruppo R., Glueck C.J., Wall E., et al. Legg-Perthes disease in three siblings, two heterozygous and one homozygous for the factor V Leiden mutation. J Pediatr 132 (1998) 885-888
35. Balasa V.V., Gruppo R.A., Glueck C.J., et al. Legg-Calve-Perthes disease and thrombophilia. J Bone Joint Surg Am 86A (2004) 2642-2647
36. Jones L.C., Mont M.A., Le T.B., et al. Procoagulants and osteonecrosis. J Rheumatol 30 (2003) 783
37. Koo K.H., Kim R., Cho S.H., et al. Angiography, scintigraphy, intraosseous pressure, and histologic findings in high-risk osteonecrotic femoral heads with negative magnetic resonance images. Clin Orthop (1994) 127-138
38. Korompilias A.V., Gilkeson G.S., Ortel T.L., et al. Anticardiolipin antibodies and osteonecrosis of the femoral head. Clin Orthop (1997) 174-180
39. Korompilias A.V., Ortel T.L., and Urbaniak J.R. Coagulation bnormalities in patients with hip osteonecrosis. Orthop Clin North Am 35 (2004) 265-271
40. Kubo T., Tsuji H., Yamamoto T., et al. Antithrombin III deficiency in a patient with multifocal osteonecrosis. Clin Orthop (2000) 306-311
41. Kutlar A., Kutlar F., Turker I., et al. The methylene tetrahydrofolate reductase (C677T) mutation as a potential risk factor for avascular necrosis in sickle cell disease. Hemoglobin 25 (2001) 213-217
42. Bjorkman A., Svensson P.J., Hillarp A., et al. Factor V leiden and prothrombin gene mutation: Risk factors for osteonecrosis of the femoral head in adults. Clin Orthop (2004) 168-172
43. Boss J.H., and Misselevich I. Osteonecrosis of the femoral head of laboratory animals: The lessons learned from a comparative study of osteonecrosis in man and experimental animals. Vet Pathol 40 (2003) 345-354
44. Liu S.L., and Ho T.C. The role of venous hypertension in the pathogenesis of Legg-Perthes disease: A clinical and experimental study. J Bone Joint Surg Am 73 (1991) 194-200
45. Norman D., Reis D., Zinman C., et al. Vascular deprivation-induced necrosis of the femoral head of the rat: An experimental model of avascular osteonecrosis in the skeletally immature individual or Legg-Perthes disease. Int J Exp Pathol 79 (1998) 173-181
46. Zalavras C., Dailiana Z., Elisaf M., et al. Potential aetiological factors concerning the development of osteonecrosis of the femoral head. Eur J Clin Invest 30 (2000) 215-221
47. Zalavras C.G., Vartholomatos G., Dokou E., et al. Genetic background of osteonecrosis: Associated with thrombophilic mutations?. Clin Orthop (2004) 251-255
48. Jones J.J. Activating intravascular coagulation and causing nontraumatic osteonecrosis. In: Urbaniak J.R., and Jones Jr. J.P. (Eds). Osteonecrosis: Etiology, Diagnosis, and Treatment (1997), American Academy of Orthopaedic Surgeons, Rosemont, IL 89-97
49. Mont M.A., Glueck C.J., Pacheco I.H., et al. Risk factors for osteonecrosis in systemic lupus erythematosus. J Rheumatol 24 (1997) 654-662
50. Nilsson I.M., Krook H., Sternby N.H., et al. Severe thrombotic disease in a young man with bone marrow and skeletal changes and with a high content of an inhibitor in the fibrinolytic system. Acta Med Scand 169 (1961) 323-337
51. Pierre-Jacques H., Glueck C.J., Mont M.A., et al. Familial heterozygous protein-S deficiency in a patient who had multifocal osteonecrosis: A case report. J Bone Joint Surg Am 79 (1997) 1079-1084
52. Eldridge J., Dilley A., Austin H., et al. The role of protein C, protein S, and resistance to activated protein C in Legg-Perthes disease. Pediatrics 107 (2001) 1329-1334
53. Szepesi K., Posan E., Harsfalvi J., et al. The most severe forms of Perthes' disease associated with the homozygous Factor V Leiden mutation. J Bone Joint Surg Br 86 (2004) 426-429
54. Bouquot J.E., and LaMarche M.G. Ischemic osteonecrosis under fixed partial denture pontics: Radiographicand microscopic features in 38 patients with chronic pain. J Prosthet Dent 81 (1999) 148-158
55. Lieberman J.R. Core decompression for osteonecrosis of the hip. Clin Orthop (2004) 29-33
56. Kearon C., Gent M., Hirsh J., et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 340 (1999) 901-907
57. Martin J.L., Fry E.T., Sanderink G.J., et al. Reliable anticoagulation with enoxaparin in patients undergoing percutaneous coronary intervention: The pharmacokinetics of enoxaparin in PCI (PEPCI) study. Catheter Cardiovasc Interv 61 (2004) 163-170
58. Research CotBTS. Optimum duration of anticoagulation for deep-vein thrombosis and pulmonary embolism. Research Committee of the British Thoracic Society. Lancet 340 (1992) 873-876
59. Schulman S., Rhedin A.S., Lindmarker P., et al. A comparison of six weeks with six months of oral anticoagulant therapy after a first episode of venous thromboembolism: Duration of Anticoagulation Trial Study Group. N Engl J Med 332 (1995) 1661-1665
60. Schulman S. Oral anticoagulation in venous thromboembolism: Decisions based on more than mere feelings. J Intern Med 245 (1999) 399-403
61. Thaler H.W., Roller R.E., Greiner N., et al. Thromboprophylaxis with 60 mg enoxaparin is safe in hip trauma surgery. J Trauma 51 (2001) 518-521
62. Tan X., Cai D., Wu Y., et al. Comparative analysis of serum proteomes: Discovery of proteins associated with osteonecrosis of the femoral head. Transl Res 148 (2006) 114-119
63. Glueck C.J., Glueck H.I., Welch M., et al. Familial idiopathic osteonecrosis mediated by familial hypofibrinolysis with high levels of plasminogen activator inhibitor. Thromb Haemost 71 (1994) 195-198
64. Sun W., Li Z.R., Shi Z.C., et al. Changes in coagulation and fibrinolysis of post-SARS osteonecrosis in a Chinese population. Int Orthop 30 (2006) 143-146
65. Ferrari P., Schroeder V., Anderson S., et al. Association of plasminogen activator inhibitor-1 genotype with avascular osteonecrosis in steroid-treated renal allograft recipients. Transplantation 74 (2002) 1147-1152
66. Miyanishi K., Kamo Y., Ihara H., et al. Risk factors for dysbaric osteonecrosis. Rheumatology (Oxf) 45 (2006) 855-858
67. Bjorkman A., Svensson P.J., Hillarp A., et al. Factor V leiden and prothrombin gene mutation: Risk factors for osteonecrosis of the femoral head in adults. Clin Orthop Relat Res 425 (2004) 168-172
68. Glueck C.J., Freiberg R.A., Fontaine R.N., et al. Hypofibrinolysis, thrombophilia, osteonecrosis. Clin Orthop Relat Res 386 (2001) 19-33
69. Blanche P., Si-Larbi A.G., and Jouve P. Femoral head necrosis and hyperhomocysteinemia. J Rheumatol 28 (2001) 1469
70. Glueck C.J., Shaw P., Lang J.E., et al. Evidence that homocysteine is an independent risk factor for atherosclerosis in hyperlipidemic patients. Am J Cardiol 75 (1995) 132-136
71. Bank I., Libourel E.J., Middeldorp S., et al. Elevated levels of FVIII:C within families are associated with an increased risk for venous and arterial thrombosis. J Thromb Haemost 3 (2005) 79-84
72. Lavigne G., Mercier E., Quere I., et al. Thrombophilic families with inheritably associated high levels of coagulation factors VIII, IX and XI. J Thromb Haemost 1 (2003) 2134-2139
73. Legnani C., Cini M., Cosmi B., et al. Risk of deep vein thrombosis: Interaction between oral contraceptives and high factor VIII levels. Haematologica 89 (2004) 1347-1351
74. Schambeck C.M., Hinney K., Haubitz I., et al. Familial clustering of high factor VIII levels in patients with venous thromboembolism. Arterioscler Thromb Vasc Biol 21 (2001) 289-292
75. Kamphuisen P.W., Eikenboom J.C., Vos H.L., et al. Increased levels of factor VIII and fibrinogen in patients with venous thrombosis are not caused by acute phase reactions. Thromb Haemost 81 (1999) 680-683
76. Berger C.E., Kroner A., Stiegler H., et al. Hypofibrinolysis, lipoprotein(a), and plasminogen activator inhibitor. Clin Orthop Relat Res 397 (2002) 342-349
77. Posan E., Szepesi K., Gaspar L., et al. Thrombotic and fibrinolytic alterations in the aseptic necrosis of femoral head. Blood Coagul Fibrinolysis 14 (2003) 243-248
78. Berger C.E., Kluger R., Urban M., et al. Elevated levels of lipoprotein(a) in familial bone marrow edema syndrome of the hip. Clin Orthop Relat Res 377 (2000) 126-131
79. Campos L.M., Kiss M.H., D'Amico E.A., et al. Antiphospholipid antibodies and antiphospholipid syndrome in 57 children and adolescents with systemic lupus erythematosus. Lupus 12 (2003) 820-826
80. Nagasawa K., Tada Y., Koarada S., et al. Prevention of steroid-induced osteonecrosis of femoral head in systemic lupus erythematosus by anti-coagulant. Lupus 15 (2006) 354-357
81. Gomes M.P., and Deitcher S.R. Risk of venous thromboembolic disease associated with hormonal contraceptives and hormone replacement therapy: A clinical review. Arch Intern Med 164 (2004) 1965-1976
82. Glueck C.J., Haque M., Winarska M., et al. Stromelysin-1 5A/6A and eNOS T-786C polymorphisms, MTHFR C677T and A1298C mutations, and cigarette-cannabis smoking: A pilot, hypothesis-generating study of gene-environment pathophysiological associations with Buerger's disease. Clin Appl Thromb Hemost 12 (2006) 427-439
83. Yoon S., Shin C., Park H.Y., et al. Endothelial nitric oxide synthase gene is associated with vessel stenosis in Korean population. Clin Chim Acta 353 (2005) 177-185
84. Nakayama M., Yasue H., Yoshimura M., et al. T(-786)-> C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with myocardial infarction, especially without coronary organic stenosis. Am J Cardiol 86 (2000) 628-634
85. Loscalzo J. Nitric oxide insufficiency, platelet activation, and arterial thrombosis. Circ Res 88 (2001) 756-762
86. Aicher A., Heeschen C., Mildner-Rihm C., et al. Essential role of endothelial nitric oxide synthase for mobilization of stem and progenitor cells. Nat Med 9 (2003) 1370-1376
87. Namba T., Koike H., Murakami K., et al. Angiogenesis induced by endothelial nitric oxide synthase gene through vascular endothelial growth factor expression in a rat hindlimb ischemia model. Circulation 108 (2003) 2250-2257
88. Samuels A., Perry M.J., Gibson R.L., et al. Role of endothelial nitric oxide synthase in estrogen-induced osteogenesis. Bone 29 (2001) 24-29
89. Hofmann S., and Mazieres B. [Osteonecrosis: Natural course and conservative therapy]. Orthopade 29 (2000) 403-410
90. Koo K.H., Kim R., Ko G.H., et al. Preventing collapse in early osteonecrosis of the femoral head: A randomised clinical trial of core decompression. J Bone Joint Surg Br 77 (1995) 870-874
91. Stulberg B.N., Davis A.W., Bauer T.W., et al. Osteonecrosis of the femoral head: A prospective randomized treatment protocol. Clin Orthop (1991) 140-151
92. Hresko M.T., McDougall P.A., Gorlin J.B., et al. Prospective reevaluation of the association between thrombotic diathesis and Legg-Perthes disease. J Bone Joint Surg Am 84A (2002) 1613-1618
93. Boss J.H., Misselevich I., Bejar J., et al. Experimentally gained insight-based proposal apropos the treatment of osteonecrosis of the femoral head. Med Hypotheses 62 (2004) 958-965
94. Brenig B., Leeb T., Jansen S., et al. Analysis of blood clotting factor activities in canine Legg-Calve-Perthes' disease. J Vet Intern Med 13 (1999) 570-573
95. Laroche M. Intraosseous circulation from physiology to disease. Joint Bone Spine 69 (2002) 262-269
96. Norman D., Miller Y., Sabo E., et al. The effects of enoxaparin on the reparative processes in experimental osteonecrosis of the femoral head of the rat. Apmis 110 (2002) 221-228